Adlyxin vs Wegovy

Adlyxin (lixisenatide) is a once-daily injection made by Sanofi for treating type 2 diabetes, while Wegovy (semaglutide) is a once-weekly injection from Novo Nordisk approved for long-term weight management in obesity and to lower cardiovascular risk. Both are given under the skin, but Adlyxin uses lixisenatide and Wegovy uses semaglutide, and they have different dosing schedules and approved uses.

AI summary of the sources below.